Alkermes Plc is driven by a strong set of values and corporate philosophy. The company places emphasis on innovation, collaboration, and a patient-centered approach. Alkermes is committed to developing groundbreaking therapies and technologies to improve the lives of people with serious and complex medical conditions. With a focus on research excellence, they strive to bring forward solutions that address unmet medical needs. Alkermes values integrity, transparency, and accountability in all aspects of their work. By investing in their employees, fostering a diverse and inclusive culture, and engaging with stakeholders, Alkermes Plc aims to make a lasting positive impact in the healthcare industry.

Alkermes Plc is primarily present in the United States.

Some significant milestones achieved by Alkermes Plc include the approval of VIVITROL for the prevention of opioid relapse, the launch of ARISTADA for the treatment of schizophrenia, and the acquisition of Elan Drug Technologies. Furthermore, the company also secured FDA approval for BYDUREON BCise, a once-weekly treatment for type 2 diabetes, and expanded its product portfolio through collaborations and partnerships. Alkermes Plc has consistently focused on developing innovative therapies and entering strategic alliances to address unmet medical needs, establishing itself as a leading biopharmaceutical company in the industry.

Alkermes Plc is a pharmaceutical company with a rich history and strong background. Established in 1987, Alkermes has grown to become a leading biopharmaceutical firm specializing in the development and manufacturing of innovative medicines. The company is committed to making a difference in the lives of patients suffering from serious diseases, such as central nervous system (CNS) disorders and addiction. With a focus on research and development, Alkermes has successfully brought several FDA-approved therapies to market. By leveraging its expertise in drug delivery technologies, the company continues to advance its pipeline of potential treatments. Alkermes Plc is dedicated to improving health outcomes and reshaping the future of medicine.

The main competitors of Alkermes Plc in the market are AstraZeneca, Johnson & Johnson, Novartis, and Pfizer.

Alkermes Plc is primarily active in the biopharmaceutical industry.

The business model of Alkermes Plc is focused on the development and commercialization of innovative pharmaceutical products to address unmet medical needs. Alkermes is dedicated to providing solutions for patients through advanced drug delivery technologies, extensive research and development, and strategic partnerships. The company specializes in areas such as neuroscience, addiction medicine, and oncology, aiming to improve the lives of individuals suffering from a range of diseases and disorders. Alkermes Plc strives to create value for shareholders by delivering effective therapies while maintaining a strong commitment to scientific excellence and regulatory compliance.

Alkermes Plc KGV ir 10,05.

Alkermes Plc KUV ir 2,95.

AlleAktien kvalitātes vērtējums Alkermes Plc ir 6/10.

gaidāmā Alkermes Plc apgrozījums ir 1,54 miljardi USD.

gaidāmā Alkermes Plc peļņa ir 452,85 milj. USD.

Alkermes Plc is a leading company in the biopharmaceutical industry that specializes in researching, developing, and marketing drugs for the treatment of central nervous system disorders and addiction disorders. The company is headquartered in Dublin, Ireland and has global subsidiaries. The company divides its business activities into two segments: Commercial and R&D. The Commercial segment focuses on marketing drugs used for the treatment of addiction disorders such as alcohol dependence, opioid dependence, and smoking cessation. The R&D segment is dedicated to the discovery and development of drugs for the treatment of central nervous system disorders, including schizophrenia, depression, bipolar disorders, Alzheimer's, and multiple sclerosis. The company's key products include Vivitrol, Aristada, Risperdal Consta, and Ampyra. Vivitrol is the only long-acting medication approved by the US Food and Drug Administration (FDA) for treating both alcohol dependence and opioid dependence. Aristada is an injectable long-acting antipsychotic used for the treatment of schizophrenia. Risperdal Consta is a long-acting antipsychotic used for the treatment of schizophrenia and manic episodes in bipolar disorder. Ampyra is a potassium-optimized medication used for improved walking ability in patients with multiple sclerosis. In 2019, the company generated $1.17 billion in revenue. The majority of these earnings come from the sales of Vivitrol, Aristada, and Risperdal Consta. Additionally, Alkermes Plc has numerous partnerships with other companies to combine technology and research findings and develop new compounds. Overall, Alkermes Plc's business model is focused on developing and marketing innovative medications for the most common central nervous system disorders and addiction disorders. The company has a strong pipeline of product candidates focused on discovering and developing new therapies to improve clinical outcomes. Alkermes Plc has a strong market position and has the potential to further expand over time as it grows its global reach through partnerships and acquisitions.

Alkermes Plc izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Alkermes Plc vai uzņēmums nedod dividendes.

Alkermes Plc ISIN ir IE00B56GVS15.

Alkermes Plc WKN ir A1JKVH.

Alkermes Plc simbols ir ALKS.

Pēdējo 12 mēnešu laikā Alkermes Plc maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Alkermes Plc plāno maksāt dividendes 0 USD apmērā.

Alkermes Plc pašreizējā dividendu rentabilitāte ir .

Alkermes Plc maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Alkermes Plc pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Alkermes Plc tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Alkermes Plc apmērā 0 USD, kas tika izmaksāta 10.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 10.09.2024..

Pēdējās dividendes izmaksa notika 10.09.2024..

Gadā 2023, Alkermes Plc izmaksāja 0 USD dividendes.

Alkermes Plc dividendes tiek izmaksātas USD.